Artificial intelligence drives breakthrough vaccine to fight influenza and Ebola in Britain. Scientists at Cambridge and Southampton universities worked with advanced artificial intelligence technology.
Vaccine designed to offer protection against multiple viral variants and mutations collectively.
First human trials showed four doses were safe without any severe side effects. Professor Saul Faust emphasized need for adaptive, long-lasting immunity against emerging pandemics.
New vaccine uses genetic data and produces super-antigen to train immune system. After successful initial results, researchers will begin larger phase two clinical trials.